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We previously reported initial results in 102 multiple myeloma(MM) patients treated with sequential high-dose melphalanand autologous hematopoietic cell transplantation followed by
200 cGy total body irradiation with or without fludarabine 90 mg/m2
and allogeneic hematopoietic cell transplantation. Here we present long-
term clinical outcomes among the 102 initial patients and among 142
additional patients, with a median follow up of 8.3 (range 1.0-18.1)
years. Donors included human leukocyte antigen identical siblings
(n=179) and HLA-matched unrelated donors (n=65). A total of 209
patients (86%) received tandem autologous-allogeneic upfront, while
thirty-five patients (14%) had failed a previous autologous hematopoiet-
ic cell transplantation before the planned autologous-allogeneic trans-
plantation. Thirty-one patients received maintenance treatment at a
median of 86 days (range, 61-150)  after allogeneic transplantation. Five-
year rates of overall survival (OS) and progression-free survival (PFS)
were 54% and 31%, respectively. Ten-year OS and PFS were 41% and
19%, respectively. Overall non-relapse mortality was 2% at 100 days
and 14% at five years. Patients with induction-refractory disease and
those with high-risk biological features experienced shorter OS and  PFS.
A total of 152 patients experienced disease relapse and 117 of those
received salvage treatment. Eighty-three of the 117 patients achieved a
clinical response, and for those, the median duration of survival after
relapse was 7.8 years. Moreover, a subset of patients who became neg-
ative for minimal residual disease (MRD) by flow cytometry experi-
enced a significantly lower relapse rate as compared with MRD-positive
patients (P=0.03). Our study showed that the graft-versus-myeloma
effect after non-myeloablative allografting allowed long-term disease
control in standard and high-risk patient subsets. Ultra-high-risk patients
did not appear to benefit from tandem autologous/allogeneic
hematopoietic cell transplantation because of early disease relapse.
Incorporation of newer anti-MM agents into the initial induction treat-
ments before tandem hematopoietic cell transplantation and during
maintenance might improve outcomes of ultra-high-risk patients.
Clinical trials included in this study are registered at: clinicaltrials.gov iden-
tifiers: 00075478, 00005799, 01251575, 00078858, 00105001, 00027820,
00089011, 00003196, 00006251, 00793572, 00054353, 00014235,
00003954.
Long-term follow up of tandem 
autologous-allogeneic hematopoietic cell
transplantation for multiple myeloma
Enrico Maffini,1 Barry E. Storer,1,2 Brenda M. Sandmaier,1,3 Benedetto Bruno,4
Firoozeh Sahebi,5 Judith A. Shizuru,6 Thomas R. Chauncey,1,3,7
Parameswaran Hari,8 Thoralf Lange,9 Michael A.Pulsipher,10
Peter A. McSweeney,11 Leona Holmberg,1,2 Pamela S. Becker,1,3
Damian J. Green,1,3 Marco Mielcarek,1,3 David G. Maloney,1,3*
and Rainer Storb1,3*
1Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA;
2University of Washington School of Public Health, Seattle, WA, USA and 3Department of
Medicine, Seattle, WA, USA; 4University of Turin, Department of Molecular Biotechnology
and Health Sciences, Turin, Italy; 5City of Hope National Medical Center/Southern
California Kaiser Permanente Medical Group, Duarte, CA, USA; 6Stanford University, CA,
USA; 7VA Puget Sound Medical Health Care System, Seattle, WA, USA; 8Medical College
of Wisconsin, Milwaukee, USA; 9University of Leipzig, Germany; 10Children’s Hospital of
Los Angeles, CA, USA and 11Colorado Blood Cancer Institute, Denver, CO, USA
*Co-senior authors.
ABSTRACT
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a
potentially curative treatment for multiple myeloma
(MM) but its role is controversial. The first clinical experi-
ence with myeloablative regimens proved to be curative
for a small proportion of patients but was accompanied by
unacceptably high non-relapse mortality (NRM) rates.1,2
The introduction of less intensive conditioning regimens
for allogeneic HCT, which relied on graft-versus-tumor
(GvT) effects for tumor eradication, lowered NRM but at
the expense of higher disease relapse rates.3,4 In the late
1990s, combining cytoreductive high-dose chemotherapy
before autologous HCT with subsequent minimal intensi-
ty conditioning allogeneic HCT, an approach aimed at
inducing GvT effects, proved to be less toxic than mye-
loablative allogeneic HCT and was well tolerated.5,6 Seven
prospective trials compared clinical outcomes of autolo-
gous HCT versus tandem autologous/minimal intensity
allogeneic HCT in newly diagnosed MM patients and
yielded discordant results regarding depth of response,
overall survival (OS), and progression-free survival (PFS).
Differences in conditioning regimens, as well as 
graft-versus-host disease (GvHD) prophylaxis, including
ATG use, patient selection, definition of MM risk profiles,
and duration of follow up, made meaningful comparisons
between trials difficult.7-15 We previously reported initial
results in 102 MM patients given tandem high-dose mel-
phalan and autologous HCT followed by 200 cGy total
body irradiation (TBI) with or without fludarabine
90mg/m2 and HLA-matched HCT from related or unrelat-
ed donors.16 Here we update the early observations and
add results from 142 additional patients treated with the
same approach for a total of 244 patients with a median
follow up of 8.3 years (range, 1.0-18.1).
Methods 
Patients
From August 1998 to January 2016, 244 MM patients complet-
ed sequential treatment with high-dose melphalan and autolo-
gous HCT followed by 200 cGy TBI ± fludarabine and allogeneic,
granulocyte colony stimulating factor (G-CSF)-mobilized periph-
eral blood mononuclear cell (PBMC) infusion. One hundred and
sixty-four (67%) patients were transplanted at the Fred
Hutchinson Cancer Research Center (Fred Hutch), Seattle, WA,
USA, and 80 (33%) patients received their transplant at eight
other institutions. All patients included in the analysis were treat-
ed under eighteen clinical trials that were co-ordinated by Fred
Hutch, approved by each institution’s review board, and regis-
tered at “clinicaltrials.gov”. All patients and donors signed written
informed consent in accordance with the Declaration of Helsinki.
The nature of the analysis is retrospective, and we present clini-
cal data for those 244 patients who received both autologous and
allogeneic HCT. Patients' characteristics are detailed in Table 1.
Median age at diagnosis was 51 years (range, 25-67). Ninety-
seven (42%) patients had high-risk cytogenetics. Fifty-seven
(25%) had high-risk disease according to International Staging
System (ISS) stage III and 36 (16%) according to Revised ISS (R-
ISS) stage. Ninety-one (37%) had received more than one induc-
tion therapy line for unresponsive disease. A total of 209 patients
(86%) received tandem autologous-allogeneic upfront while 35
patients (14%) had failed a previous autologous HCT before the
planned autologous-allogeneic HCT.  
Definitions and risk assessment
Beta-2 (β2)-microglobulin and serum albumin values at diagno-
sis were available for 225 (92%) patients and were used to calcu-
late risk according to the ISS.17 The R-ISS was introduced in
2015,18 and we calculated it retrospectively for 217 (89%) patients.
Lactate dehydrogenase  (LDH) serum levels19 at diagnosis were
available in 216 patients. Conventional cytogenetics and/or fluo-
rescence in situ hybridization (FISH) studies at diagnosis and at any
time before allogeneic HCT were available for 232 patients. High-
risk cytogenetics were defined as follows: t(4;14);20 t(14;16);21
t(14;20)22 by FISH; del (17/17p),23 1q21 amplifications24 both by
FISH and conventional karyotyping; and non-hyperdiploid kary-
otype25 by conventional cytogenetics. Plasma cell leukemia includ-
ed circulating plasma cells ≥ 20% of complete blood count or
≥2000 plasma cells per microliter.26 Extramedullary disease at diag-
nosis was defined as extramedullary plasmacytomas.27 Patients
were considered high risk if they had one of the following: ISS
stage III, high-risk genetic lesions, extramedullary disease presen-
tation, plasma cell leukemia, LDH levels ≥ 2 upper normal limits
or failed previous autologous HCT. Ultra-high-risk was defined as
having ≥ 2 adverse factors.23,28 All patients not meeting previous
criteria were considered standard risk. 
HLA-typing
Patients and donors were matched for HLA-A, HLA-B and
HLA-C by at least intermediate resolution DNA typing and for
HLA-DRB1 and DQB1 by high-resolution techniques, as previous-
ly described.29 Donors were HLA-identical siblings in 179 cases
and HLA-matched unrelated in 65 cases; 11 unrelated donors were
mismatched with their recipients for a single HLA allele (n=7) or
antigen (n=4).
Autologous hematopoietic cell transplantation
After induction treatment, patients proceeded to mobilization
and collection of PBMC. Mobilization regimens included:
cyclophosphamide plus dexamethasone (35% of patients),
cyclophosphamide plus etoposide and dexamethasone (CED)
(24%), cyclophosphamide plus paclitaxel (16%), VTD-PACE
(bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-
cyclophosphamide-etoposide) (8%), VRD-PACE  (bortezomib-
lenalidomide-dexamethasone-cisplatin-doxorubicin-cyclophos-
phamide-etoposide) (5%), carfilzomib plus RD-PACE (lenalido-
mide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-
etoposide) (1%), cyclophosphamide plus etoposide and carboplat-
inum (CEP) (2%), bendamustine plus etoposide and dexametha-
sone (BED) (1%), Hyper-CVAD  (cyclophosphamide-vincristine-
doxorubicine-dexamethasone-adenosine arabinoside-mesna-
methotrexate) (1%), or G-CSF (10 mg/kg) alone in 7% of the
patients. After PBMC collection, patients received melphalan at
200 mg/m2 intravenously (N.B. 3 patients received melphalan 140
mg/m2 because of impaired renal function) before autologous
PBMC infusion, with a median of 7.8 (range, 2.1-30.4) × 106 CD34+
cells/kg actual body weight. 
Allogeneic hematopoietic cell transplantation
After complete recovery from autologous HCT, patients pro-
ceeded to allogeneic HCT at a median of 75 days (range, 40-281).
No further therapy was given between autologous and allogeneic
HCT. The conditioning regimen for allogeneic HCT consisted of
200 cGy TBI at 7 cGy/minute from a linear accelerator (n=163) or
two opposing Cobalt-60 sources (n=81). Recipients of unrelated
grafts (n=65) received in addition three daily doses of fludarabine
for a total of 90 mg/m2. PBMC grafts contained a median of 9.0
(range, 1.7-24.0) x 106 CD34+ cells/kg actual body weight. Post-
grafting immunosuppression included mycophenolate mofetil
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Table 1. Patients’ characteristics.
Characteristics Total (n) %
Baseline characteristics at diagnosis 244
Median age, years (range) 51 (25–67)
Male: female 143–101 59/41
Isotype
IgG 151 62
IgA 51 22
Light chains only 30 12
Non-secretory 3 1
IgD 3 1
Plasma cell leukemia 6 2
Renal failure (serum creatinine > 2 mg/dL) 39 18
LDH values ≥ 2 ULN 60/216 28
ISS 225
Stage I 72 32
Stage II 96 43
Stage III 57 25
R-ISS 217 89
Stage I 38 18
Stage II 143 66
Stage III 36 16
Cytogenetics, high-risk 97/232 42
≥ 2 high-risk cytogenetic abnormalities 31 32
del(17p) 28 29
t (4;14) 22 23
amp1q 9 9
Others [hypoploidy; t (14;16); t (14;20)] 7 7
Extramedullary disease (plasmacytomas) 50 20
Disease risk 214 88
Standard risk 62 28
High risk 73 35
Ultra-high risk 79 37
Characteristics at autologous HCT 244
Median time from diagnosis to autologous HCT, years (range) 0.8 (0.2–18.1)
Failed previous autograft 35 14
Induction regimens
VAD-based 125 51
IMiDs-based 30 12
PIs-based 15 6
IMiDs + PIs 56 24
Other (MP; HD-Dex; Dex-Cy) 18 7
Median induction lines of therapy, n (range) 1 (1–5)
Characteristics at allogeneic HCT 244
Median age, years (range) 53 (25–71)
Patients > 60 years old 50 20
Median time from autograft to allogeneic HCT, days (range) 75 (40–281)
Patients with induction therapy-refractory disease 42 17
Sibling, unrelated donor 179 – 65 73/27
Median CD34+/kg infused, n (range) 9.00 x 106 (1.7–24.0)
Median CD3+/kg infused, n (range) 3.28 x 108 (0.4–11.7)
continued on the next page
(MMF) (from a minimum of 28 days for sibling recipients to a
maximum of 180 days for unrelated donors) and a calcineurin
inhibitor (CNI) of either cyclosporine (n=176) or tacrolimus (n=56)
for a minimum of 80 days with a subsequent taper to 180 days, as
previously described.5 Twelve patients received sirolimus in addi-
tion to MMF and CNI at the dose of 2 mg orally once daily from
day -3 to day +80 (n=4), day +180 (n=6), and day +365 (n=2).30
Thirty-one patients included in the analysis also received borte-
zomib (n=21; either at 1.6 mg/m2 intravenously or 2.6 mg/m2 sub-
cutaneously every 14 days for up to 9 months) or lenalidomide
(n=10; starting dose of 10 mg per day, range: 5-25 mg per day, on
days 1-21 of each 28-day cycle, for 12 cycles of planned treatment)
as maintenance treatment after allogeneic HCT, per protocol, as
specified in the Results section.
Chimerism evaluation
Donor chimerism was assessed at days 28, 56, 84, 180 and 365
after allogeneic HCT on peripheral blood CD3+ T lymphocytes
and CD33+  myeloid cells, while unfractionated marrow was ana-
lyzed only on day +84.  This involved FISH analyses in sex-mis-
matched pairs and polymerase chain reaction-based studies of
polymorphic microsatellite regions in all other patients.31
Disease response assessment
Disease responses were based on the 2016 Uniform Response
Criteria developed by the International Multiple Myeloma
Working Group32 with some minor modifications. Complete
response (CR) required negative immunofixation (IFIX) on the
serum and urine, disappearance of any soft tissue plasmacytomas
and/or osteolytic bone lesions, <5% plasma cells in bone marrow
aspirates, and no evidence of clonal disease on flow cytometry
analysis; very good partial response (VGPR) was defined as serum
and urine M-protein detectable by IFIX but not on electrophoresis
(SPEP) or ≥90% reduction in serum M-protein plus urine M-pro-
tein level <100 mg/24 hours (h). Partial response (PR) required
≥75% reduction of serum M-protein and reduction in 24 h urinary
M-protein by ≥90% or to <200 mg/24 h and no increases in sizes
or numbers of soft tissue plasmacytomas and/or lytic bone lesions;
stable or progressive disease (PD) before autologous HCT was
defined as chemo-refractory disease, while the achievement of at
least a PR as chemotherapy-sensitivity disease. Patients were eval-
uated both before autologous HCT and before allogeneic HCT in
order to estimate the baseline levels of disease activity before each
transplantation, again on days 28, 56, 84 and 180 after allogeneic
HCT, and thereafter on a clinical basis. Disease evaluation includ-
Tandem transplantation for multiple myeloma
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CMV serostatus 212 87
Recipients positive 113 53
Recipients negative with Donor positive 30 14
Recipients and Donor negative 69 33
HCT-CI score 206/244 84
0 59 29
1 or 2 79 38
≥ 3 68 33
KPS scale < 80% 42/218 19
Allogeneic HCT conditioning
TBI 200 cGy 164 67
TBI 200 cGy + fludarabine 90mg/m2 80 33
GvHD prophylaxis 
MMF + CSP 176 72
MMF + TAC 56 23
MMF + CSP/TAC + SRL 12 5
Median follow up for surviving patients years(range) 8.3 (1.0–18.1)
CMV: cytomegalovirus; CSP: cyclosporine; Dex-Cy: dexamethasone + cyclophosphamide; GvHD: graft-versus-host disease; HCT: hematopoietic cell transplantation; HCT-CI:
hematopoietic cell transplantation-comorbidity index; HD-Dex: high-dose dexamethasone; IMiDs: immunomodulatory drugs; KPS: Karnofsky Performance Status; LDH: lactate
dehydrogenase; MMF: mycophenolate mofetil; MP: melphalan + prednisone; n: number; PIs: proteasome inhibitors; R-ISS: Revised-International Staging System; SRL: sirolimus;
TAC: tacrolimus; TBI: total body irradiation; ULN: upper limit of normal; VAD: vincristine + doxorubicin + dexamethasone.
Table 2. Disease response.
Disease status Status at autologous HCT Status at allogeneic HCT Best response after allogeneic HCT
n= 244 % n= 244 % n= 244 %
CR 12 5 62 26 111 46
VGPR 35 14 47 19 42 17
PR 106 42 93 38 49 20
RD/PD 91 39 42 17 42 17
CR: complete remission; HCT: hematopoietic cell transplantation; n: number; PD: progressive disease; PR: partial response; RD: refractory disease; VGPR: very good partial
response.
ed serum and urine SPEP and IFIX for M-protein detection and
quantification, plasma cell quantification, cytogenetics and FISH
studies in the marrow, and radiological imaging to assess for oste-
olytic lesions/plasmacytomas whenever appropriate. Six-color
multi-parameter flow cytometry analysis of marrow cells for
detection of minimal residual disease (MRD) was carried out for a
subset of patients who achieved IFIX-negative CR after tandem
autologous-allogeneic HCT and were treated at Fred Hutch
(n=28). Samples were analyzed at the University of Washington
Hematopathology Laboratory. The sensitivity of the flow cytom-
etry assay for plasma cell neoplasms ranged from 0.01 to 0.001%.
MRD negativity (MRDNEG) status was defined as no evidence of
quantifiably detectable disease.
Graft-versus-host disease evaluation
Grading of acute and chronic GvHD was performed according
to previously described methods.33,34 Information regarding the
administration of systemic immunosuppressive treatment for
GvHD was collected prospectively. 
End points and statistical methods
Primary objectives of this study were OS and PFS. Secondary
end points included: cumulative incidences of acute GvHD, chron-
ic GvHD, NRM, disease response, and disease relapse. We also
examined response to treatment and survival among those
patients who experienced disease relapse after allogeneic HCT.
OS, PFS, and NRM were defined as the times from allogeneic
HCT to death, death or progression, and death without progres-
sion, respectively. Probabilities of OS and PFS were estimated
using the Kaplan-Meier method; cumulative incidences of relapse,
NRM, and GvHD were estimated taking competing risks into
account. Cox and Fine & Gray regression models were used to
E. Maffini et al.
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Figure 1. Prevalence curve of patients alive requiring immunosuppressive treat-
ments (IST) for chronic graft-versus-host-disease (GvHD). Black line represents
the standard survival curve (OS) for the entire patient cohort (n=244). Patients
alive and on IST for chronic GvHD treatment are represented by the blue curve.
The graphical difference between the two curves is the fraction of patients alive
and off IST, during different time points.
Table 3. Causes of death after allogeneic hematopoietic cell transplantation.
Events                                                                                 Number                                                        Time (months) after allografting
Disease progression                                                                             104                                                                         Median time: 36.6 (range: 1–179)
NRM                                                                                                            40                                                                          Median time: 10.9 (range: 2–183)
Acute GvHD                                                                                               10                                                                                              Median: 3.5 
Gut GvHD                                                                                                 4                                                                                                (3, 3, 3, 4)
Cerebral aspergillosis                                                                           1                                                                                                      (5)
Cerebral ischemia r/to septic emboli                                               1                                                                                                      (3)
Aspergillosis + TTP/HUS                                                                      1                                                                                                      (6)
CMV disease                                                                                            2                                                                                                    (2, 4)
Sepsis                                                                                                       1                                                                                                      (5)
Chronic GvHD                                                                                          20                                                                                              Median: 12
Respiratory syncytial virus pneumonia                                             1                                                                                                      (7)
Sepsis                                                                                                       7                                                                                     (6, 8, 18, 23, 11, 58, 15)
Bronchiolitis obliterans                                                                        6                                                                                      (9, 10, 14, 16, 37, 112)
Pneumonia                                                                                               5                                                                                          (7, 7, 11, 13, 142)
Invasive aspergillosis                                                                            1                                                                                                     (11)
Second cancers                                                                                        5                                                                                              Median: 121
Lung cancer                                                                                             2                                                                                                   (4, 13)
Esophageal cancer                                                                                 1                                                                                                    (130)
Pancreatic cancer                                                                                  2                                                                                                (121, 182)
Other                                                                                                           5                                                                                               Median: 45
Traumatic head injury                                                                           1                                                                                                     (45)
Severe grand mal seizures                                                                  1                                                                                                     (64)
ARDS and alveolar hemorrhage                                                          2                                                                                                    (3, 3)
Congestive heart failure                                                                       1                                                                                                    (136)
ARDS: acute respiratory distress syndrome; CMV: cytomegalovirus; GvHD: graft-versus-host disease; NRM: non-relapse mortality; TTP/HUS: thrombotic thrombocytopenic purpu-
ra and hemolytic-uremic syndrome. 
determine factors influencing HCT outcomes in univariate and
multivariate analyses. Multivariate risk factors analysis included
only variables significant at 0.05 level in univariate analysis for any
OS, PFS, and relapse incidence. Acute GvHD, chronic GvHD, and
post-transplant MM maintenance treatment (administered to 31
patients) were considered as time-dependent co-variates. Since no
single variable, other than grade II-IV acute GvHD, had a signifi-
cant correlation with NRM by univariate analysis, NRM was not
incorporated into multivariate analysis.
Results
Disease response before and after autologous
hematopoietic cell transplantation 
Disease responses are summarized in Table 2. At the
time of autologous HCT, there were no statistical signifi-
cant differences among 125 patients who received vin-
cristine – doxorubicin – dexamethasone (VAD)-based
induction, mainly between 1998 and 2006, and those
treated with immunomodulatory/proteasome inhibitor
(n=101) triplet regimens (2006-2016) in terms of response
rate: 74 (59%) versus 68 (68%) achieved at least a PR,
respectively, and only 12 patients were in CR before autol-
ogous HCT. Of the 18 who received other induction ther-
apies (melphalan plus prednisone, n=6; high-dose dexam-
ethasone only, n=11; high-dose dexamethasone plus
cyclophosphamide, n=1), 11 achieved PR and 7 PD. After
high-dose melphalan and autologous HCT, 62 patients
(26%) were in CR, 47 (19%) VGPR, 93 (38%) PR, and 42
(17%) had PD. 
Allogeneic hematopoietic cell transplantation
Sixty-seven percent of the patients had allogeneic HCT
within the first 3 months after autologous HCT, 29%
between 3 and 6 months and 4% beyond 6 months.
Reasons for allogeneic HCT delay included: delayed
hemopoietic recovery (59%), abnormal hepatic/renal
function (15%), active infection requiring intravenous
antibiotics (13%), persisting mucositis (4%),
cytomegalovirus reactivation requiring intravenous thera-
py (6%), and patient choice (3%). Results after allogeneic
HCT are presented with a median follow up of 8.3 (range,
1.0–18.1) years among surviving patients. 
Engraftment and GvHD - All 244 patients achieved sus-
tained engraftment after allogeneic HCT. Median values
of donor chimerism on CD3+ T cells in peripheral blood
on days 28, 84, and 180 were 89%, 95%, and 100%,
respectively, while median values of donor chimerism of
CD33+ myeloid cells were 96%, 100%, and 100%, respec-
tively. The cumulative incidence of grade II-IV acute
GvHD was 44% with a median onset of 39 days (range, 6-
124), of which 33% was grade II, 7% grade III, and 4%
grade IV. Sibling recipients (n=176) experienced less grade
II-IV acute GvHD than unrelated (n=65) recipients (38%
vs. 64%; P<0.001). Of the 228 patients who survived
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Figure 2. Long-term clinical outcomes after tandem autologous-allogeneic hematopoietic cell transplantation (HCT) for the entire population and stratified for dis-
ease-risk groups. Non-relapse mortality (NRM) and relapse incidence (A). Overall survival (OS) and progression-free survival (PFS) for the entire cohort (n=244) (B).
OS (C) and PFS (D) for disease-risk stratification groups with standard-risk (n=62), high-risk (n=73), and ultra-high-risk (n=79). 
A B
C D
longer than 100 days post-transplant, 122 developed
chronic GvHD requiring treatment. The cumulative inci-
dence of extensive chronic GvHD requiring systemic
immunosuppression was 46% [95% Confidence Interval
(CI): 39.5-52.4] at one year and 55% (95%CI:  47.7-60.7)
at five years. No differences in chronic GvHD incidence
were observed between related and unrelated recipients.
Of all the surviving patients, 24% required immunosup-
pressive therapy for chronic GvHD at five years, 12% at
ten years and 4% at 15 years, respectively (Figure 1).
Non-relapse mortality - NRM was 2% at day 100, 14% at
five years and 15% at ten years after allogeneic HCT,
respectively (Figure 2A). GvHD and treatment-related
complications accounted for 30 of the 40 non-relapse-
related deaths, while 5 patients died of secondary malig-
nancies (Table 3) between 0.3 and 15.2 years after allo-
grafting and the remaining 5 died from other causes. Of
note, no secondary hematologic cancers were observed.
By univariate analysis, only the finding of grade II-IV acute
GvHD [Hazard Ratio (HR) 3.12; 95%CI:  1.6-6.2; P=0.001]
and ISS stage III at diagnosis (HR: 3.92; 95%CI: 2.0-7.6;
P<0.001) significantly impacted NRM. Chronic GvHD,
poor performance status, and comorbidities were not
associated with higher risk of NRM.
Disease response and relapse - After allogeneic HCT, 111
(46%) patients achieved CR, 42 (17%) achieved VGPR, 49
achieved (20%) PR, and 42 (17%) failed to achieve a
response (Table 2). Median time to best response after
allografting was 6.68 months (range, 0.7-73.4). Among the
111 patients who achieved a CR as their best response, 46
remained in CR while 65 relapsed. Accordingly, the 10-
year relapse incidence was 66% (95%CI:  59-72) (Figure
2A). Nineteen (12%) patients had late relapses beyond
five years after allogeneic HCT (range, 5.2-9.8 years).
Among patients who did not have extramedullary disease
at diagnosis and who relapsed after allogeneic HCT
(n=112), 28 (25%) showed extramedullary relapse (23
without evidence of marrow involvement). By multivari-
ate analysis, ultra-high-risk patients (HR: 4.99; 95%CI:
2.9-8.7) and those with induction therapy-refractory dis-
ease before allografting (HR: 5.35; 95%CI: 3.4-8.6) had
significantly higher relapse risks. The development of
chronic GvHD did not protect against disease relapse (HR,
0.92; 95%CI: 0.6-1.3; P=0.66) (Table 4). Among patients
with available marrow samples who achieved CR after
allogeneic HCT (n=28), those with positive MRD (MRD-
POS) detected by flow cytometry (n=15) experienced a high-
er disease relapse rate than MRNEG patients (n=13) (HR:
10.4; 95%CI: 1.3-82.2; P=0.03). 
Overall and progression-free survival - With a median fol-
low up of 8.3 years (range, 1-18.1), median OS and PFS
were 6.4 (95%CI: 3.9-9.2) years and 1.9 (95%CI: 1.4-2.6)
years, respectively. Five-year OS and PFS were 54%
(95%CI: 48-60) and 31% (95%CI: 25-36), respectively.
Ten-year OS was 41% (95%CI: 34-48) and PFS was 19%
(95%CI:13-24) (Figure 2B).  By univariate analyses, ISS
and R-ISS stage III, LDH >2 upper normal limits, high-risk
cytogenetics, grade II-IV acute GvHD, extramedullary dis-
ease, induction-refractory disease, and a prior failed autol-
ogous HCT were all strongly associated with inferior OS
and PFS. By multivariate analysis, only high and ultra-high
disease risk and induction-refractory disease remained
strongly associated with worsened rates of OS and shorter
PFS (Table 4). Among patients with standard-risk disease
(n=62), the median OS was not reached, whereas the
median PFS was 6.5 (95%CI: 4.2-9.6) years. High-risk
patients (n=73) experienced a median OS of 8.4 (95%CI:
3.9-10.2) years with a PFS of 2.5 (95%CI: 1.4-3.7) years,
while ultra-high-risk patients (n=79) had a 2.3 (95%CI:
1.2-3.3) years median OS and 0.7 (95%CI: 0.6-0.9) year
PFS (Figure 2C and D). Patients who proceeded to tandem
transplantation after a previously failed autologous HCT
(n=35) had poor outcomes, with a median OS of 1.2 years
(95%CI: 0.6-2.0) years and a median PFS of 0.6 years
(95%CI: 0.2-0.7). Similarly, patients who progressed after
melphalan and autologous HCT (n=42) did poorly, having
a median OS of 1.2 years (95%CI: 0.5-3.0) and median PFS
of only 0.4 years (95%CI: 0.2-0.6) (Figure 3A and B); medi-
an time to relapse was 4.5 (0.1-61.9) months. Patients with
extramedullary disease at diagnosis (n=50) showed medi-
an OS and PFS of 2.03 (95%CI: 1.0-3.5) and 0.95 (95%CI:
0.46-1.1) years, respectively. Patients achieving CR after
allogeneic HCT displayed superior OS (median 14.9 vs. 3.2
years; HR: 3.2; 95%CI: 2.2-4.6), and PFS (median 6.9 vs.
0.9 years; HR: 4.6; 95%CI: 3.4-6.6) as compared with
those who did not enter CR.
Maintenance treatments - Between May 2009 and
February 2016, 31 patients received post-transplant main-
tenance treatment with bortezomib (n=21) or lenalido-
mide (n=10) starting between 61 and 150 days  (median
E. Maffini et al.
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Figure 3. Kaplan-Meier estimates of overall survival (OS) and progression-free
survival (PFS) stratified for disease-status after autologous hematopoietic cell
transplantation (HCT). Overall survival (OS) (A) and progression-free survival
(PFS) (B) among patients with progressive disease (n=42; blue line) and respon-
ders (n=202; black line).
A
B
86)  after allogeneic HCT. Seventeen patients completed
the planned treatment (lenalidomide, n=7; bortezomib,
n=10). Disease progression was the reason for early treat-
ment discontinuation in 9 of the treated patients. One
patient on lenalidomide stopped the treatment due to an
acute GvHD flare which was successfully treated. Other
causes included: patient choice (n=1), diarrhea not GvHD-
related (n=1), severe headache (n=1), and liver function
abnormalities (n=1). By univariate analysis, maintenance
therapy was not associated with any clinical outcome.
Median OS was 6.3 (95%CI: 3.6-not reached). There was
no difference in terms of median PFS between those
patients who received maintenance treatment (n=31) after
allogeneic HCT (2.56 years; 95%CI: 0.88-4.22) and those
(n=175) who achieved a response after allogeneic HCT
but did not receive maintenance (2.59 years; 95%CI: 1.86-
3.50).
Survival after disease progression - One hundred and fifty-
two patients (62%) experienced relapse or progression.
Median survival after the first relapse/progression was 2.9
years (95%CI:  1.9-3.7) for the entire cohort (n=152)
(Figure 4). Twenty-eight of the 152 received palliative best
supportive care and died after a median of 2.1 months.
One patient died during conditioning for a planned subse-
quent allogeneic HCT. Data on salvage therapy were not
available for 5 patients (3%). One hundred and nineteen
patients received a total of 228 lines of treatment, with a
median of two lines (range, 1-9) of therapy each.
Treatments included lenalidomide (n=67), bortezomib
(n=54), thalidomide (n=36), alkylators/anthracyclines
(n=27), pomalidomide (n=10), carfilzomib (n=9), daratu-
mumab (n=1), and others (n=6). Twenty-seven (23%) of
the 119 treated patients were unresponsive to salvage
treatments and died after a median of 9.2 months (95%CI:
5.5-12.0), while the 83 patients who achieved at least a PR
had a median survival of 7.8 (95%CI: 5.9-10.6) years.
Disease responses for those 83 patients included: 29 CR
(15 of these patients are still in CR, 4 are alive with PD,
and 10 have since died), 13 VGPR (3 are still in VGPR, 2
are alive with PD, and 8 have since died), and 41 PR (9 cur-
rently with stable disease, 10 alive with PD, while 22 have
since died). Data on disease response after salvage treat-
ments were not available for 9 patients. Eighteen patients
received a median of 2 donor lymphocyte infusions
(range, 1-4) (preceded by chemotherapy in 9 patients) after
a median of 1.4 years post-allografting (range, 0.9-8.3).
Four of these achieved a partial response, while the
remaining 14 did not show a response. Patients who
relapsed during the first 18 months after allogeneic HCT
(n=82) had a worsened prognosis (median survival after
relapse/progression: 1.1 years; 95%CI: 0.6-1.9) compared
to those (n=70) who relapsed beyond 18 months after
allogeneic HCT (median survival after relapse/progres-
sion: 7.2 years; 95%CI: 4.3-10.6; P<0.0001). 
Discussion
Advances in the understanding of MM biology have led
to novel treatments that have dramatically prolonged PFS
and OS. First-line autologous HCT has remained standard
of care for eligible patients. Three randomized trials
reported significantly superior median PFS, ranging
between 25 and 32 months, as compared to conventional
chemotherapy.35-37 PFS was further improved up to 43-50
months after “new drugs” were employed both in the
induction and consolidation/maintenance phases.38-40
Whether double autologous transplants are superior to a
single autograft remains to be determined.41-43 In our series,
an overall median PFS of 1.9 years may appear modest.
However, when applying retrospective risk stratification,
median PFS was 6.5 years in standard-risk patients, 2.5
year in high-risk patients, and 0.7 years in ultra-high-risk
patients. Extramedullary relapse without marrow relapse
has been frequent after allografting.44-46 Sanctuary sites
may be less accessible to graft-versus-myeloma effects
than marrow. Of note, extra-medullary relapse occurred in
25% of current patients who did not have extramedullary
involvement at diagnosis. Overall NRM was low (2% at
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Figure 4. Survival from disease relapse/progression after allogeneic
hematopoietic cell transplantation for an overall 152 relapsed patients. 
Table 4. Multivariate† risk factors in 211 patients.
Relapse Progression-free survival Overall survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
High risk 1.74 (1.1–2.9) 0.03 1.62 (1.1–2.5) 0.03 2.48 (1.4–4.3) 0.001
Ultra-high-risk 4.99 (2.9–8.7) <0.0001 3.47 (2.1–5.7) <0.0001 3.87 (2.1–7.2) <0.0001
Chemorefractory 5.35 (3.4–8.6) <0.0001 4.61 (3.0–7.1) <0.0001 3.28 (2.1–5.2) <0.0001
Age ≥ 60 years at allo HCT 1.16 (0.8–1.8) 0.48 1.22 (0.8–1.8) 0.29 1.33 (0.9–2.0) 0.18
Unrelated donor 1.54 (1.0–2.3) 0.04 1.47 (1.0–2.1) 0.04 1.32 (0.9–2.0) 0.20
HR: Hazard Ratio; CI: Confidence Interval; allo HCT: allogeneic hematopoietic cell transplantation. †Includes variables significant at 0.05 level in univariate analysis for any end
point.
100 days and 14% at 5 years) and, with a median follow
up of 8.3 years, median OS was 6.4 years. By risk stratifi-
cation, median OS was not reached in standard-risk
patients, while high-risk and ultra-high-risk patients had
worse outcomes with median OS of 8.4 and 2.3 years,
respectively. Of note, only a minority of our patients
achieved a complete remission after induction treatments,
and a subset of them received tandem autologous-allo-
geneic HCT beyond first line. Moreover, none of our
patients received recently Food and Drug Administration-
approved monoclonal antibodies, such as daratumumab
and elotuzumab, which have been associated with
remarkable response rates.
Although restricted to a small group of patients, we
demonstrated that the achievement of MRDNEG predicted
long-term CR among patients with IFIX-negative CR after
autologous HCT. Whether long-term persistence of 
MRDNEG indicates disease eradication is unclear. Multi-
parameter flow cytometry and PCR-based methods are
two sensitive techniques currently used to evaluate MRD
in MM. Evaluation of MRD through immuno-phenotyp-
ing is more broadly available than PCR-based methods. In
the present series, patients who achieved MRDNEG by flow
cytometry experienced a significantly lower relapse rate as
compared with MRDPOS patients (P=0.03). These findings
confirm previous observations by Giaccone et al. who
reported on the clinical impact of immuno-phenotypic
remission after allografting in 66 MM patients.47
Conditioning was 2 Gy TBI-based in 55 of the 66 patients.
After a median follow up of 7.1 years, patients who
achieved conventional CR and MRDNEG disease status had
better clinical outcomes in terms of OS (median not
reached) and PFS (median 59 months). Moreover, Ladetto
et al. reported a PCR-based molecular analysis of MRD
after minimal-intensity TBI-based conditioning in newly
diagnosed patients who had not been exposed to new
drugs.48 After a median follow up of 12.1 years, the medi-
an OS and PFS were not reached in patients who achieved
PCR MRD negativity. Overall, MRD studies support the
hypothesis that potentially curative graft-versus-myeloma
effects after minimal intensity conditionings allowed long-
term disease control and persistent yet non-progressive
MRD in a subset of MM patients. 
Whether graft-versus-myeloma effects are associated
with chronic GvHD is still a subject of debate. Ringdén et
al. evaluated the impact of acute and chronic GvHD on
relapse and survival in 177 patients transplanted from
HLA-identical siblings after non-myeloablative or
reduced-intensity conditioning.49 Acute GvHD was associ-
ated with a significantly higher risk of TRM, while limited
chronic GvHD significantly reduced the risk of relapse.
However, the reduced relapse risk did not translate into
better OS. Crawley et al. reported that chronic GvHD was
associated with better PFS and OS after reduced-intensity
conditioning.3 In the present study, we report an incidence
of chronic GvHD of 55%, which, as in other comparative
prospective trials,7,9 was not associated with better disease
control. A trend towards higher chronic GvHD rates after
the introduction of minimal/reduced-intensity condition-
ing was shown in a Center for International Blood and
Marrow Transplant Research (CIBMTR) analysis on 1207
MM recipients between 1989 and 2005. Overall, 50% of
the patients who survived at least five years in the 2001-
2005 cohort developed chronic GvHD, 65% of whom had
extensive involvement.4 Discontinuation of all immuno-
suppressive agents is a surrogate for achieving immunotol-
erance, and is associated with improved quality of life.
Importantly, only a minority of current survivors
remained on immunosuppressive drugs long-term: 24%,
12%, and 4% at five, ten, and 15 years, respectively. 
Indications for allografting in MM have greatly changed
over the years due to remarkable advances in the under-
standing of disease biology and new treatment modalities
that increased median survival rates up to 8-10 years in
standard-risk patients. However, relapse has remained a
major issue, and poor outcomes have been observed in
patients with high-risk/ultra-high-risk disease.50
Interestingly, Sobh et al. described trends and clinical out-
comes of allogeneic HCT for MM in Europe between
1990 and 2012.51 The study included 7333 patients who
were divided into 3 groups: 1) allogeneic HCT upfront
(n=1924); 2) tandem autologous-allogeneic HCT (n=2004);
and 3) allogeneic HCT as a second-line treatment or
beyond (n=3405). A steady increase in numbers of allo-
geneic HCT over the years was observed. The use of
upfront allogeneic HCT increased up to the year 2000, fol-
lowed by a decline thereafter, representing 12% of allo-
geneic HCT performed in 2012. Tandem autologous-allo-
geneic HCT peaked around the year 2004 and represented
19% of allogeneic HCTs in 2012. Allogeneic HCT as sal-
vage after at least one autograft has steadily increased over
recent years and represented 69% of allogeneic HCTs in
2012. Unfortunately, only a minority of these patients
were enrolled in controlled trials and remarkable hetero-
geneity in using allogeneic HCT was observed among dif-
ferent European countries. 
The potential role combining “new drugs” with 
graft-versus-myeloma effects has not yet fully been
explored. In a Phase II study, the feasibility of using borte-
zomib within a reduced-intensity conditioning regimen
and as maintenance therapy post allograft was evaluated.52
Conditioning consisted of fludarabine, melphalan, and
bortezomib, while maintenance treatment consisted of 7
cycles of bortezomib. Sixteen high-risk patients who had
relapsed after an autograft were prospectively enrolled.
Nine of 16 patients (56%) achieved CR and 5 of 16 (31%)
achieved PR after allogeneic HCT. In this heavily pre-
treated high-risk population, 3-year cumulative incidences
of NRM, relapse, and OS were 25%, 54% and 41%,
respectively. For the first time, this trial showed safety and
efficacy of an intensified conditioning with a “new drug”
in poor prognosis patients. Moreover, the concept of
maintenance treatment after an allograft was also intro-
duced. Our group recently published the results of a
prospective Phase II single-center trial evaluating borte-
zomib as maintenance treatment after tandem autolo-
gous/allogeneic HCT for high-risk MM. At a median fol-
low up of 51 months, a net benefit in terms of OS and PFS
was shown among newly diagnosed patients over those
with relapsed/persistent disease, suggesting that borte-
zomib maintenance may add a survival benefit among
untreated patients. Treatment-related toxicity was limit-
ed, without any GvHD exacerbations.53 Different observa-
tions were reported with immunomodulatory drugs.
Somewhat compromised by an unacceptably high drop-
out rate, the Phase III BMT CTN 0102 trial did not show
a benefit of thalidomide maintenance after tandem autol-
ogous/allogeneic HCT.13 Lenalidomide maintenance was
evaluated in a study by the HOVON Group54 where the
unexpectedly high toxicity profile, mainly exacerbation of
E. Maffini et al.
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acute GvHD, led to early discontinuation in 87% of the
patients. In a Phase II CIBMTR trial on 30 patients,55 the
use of lenalidomide was feasible if given at lower doses. A
lower toxicity profile of lenalidomide maintenance was
also reported by Kroger et al. in relapsed patients after an
autograft and rescued with a myeloablative allograft.56
Importantly, a synergy between new drugs and graft-
versus-myeloma effects with a far safer toxicity profile has
been described in the relapsed setting, suggesting that allo-
geneic-HCT and new drugs may be complementary. In
our study, the median duration of survival of 7.8 years
from the first relapse/progression among patients who
achieved a response to salvage treatments supports this
concept. These findings have been confirmed by two
other recent reports.57,58 An update of an Italian study
focused on the role of “new drugs” in long-term clinical
outcomes.57 Median OS from first relapse was 7.5 years in
the autologous/allogeneic group and two years in the tan-
dem autologous group (P=0.01). Htut et al. compared the
post-relapse OS after autologous/allogeneic HCT versus
tandem autografts in patients reported to CIBMTR
between 2000 and 2010.58 Six-year post-relapse OS was
significantly better in the autologous/allogeneic group as
compared with the tandem autografts group, 44% versus
35%, respectively (P=005). Taken together, these findings
suggest a synergy between new agents and the donor-
derived immunological milieu. 
The current role of allografting in multiple myeloma is
controversial though the procedure is still used at many
centers. Prospective studies were designed before agents
with potent anti-myeloma activity became readily avail-
able. However, despite the recent introduction of very
effective pharmacological therapies, there remains a sub-
set of high-risk patients accounting for about 10-15% of
new diagnoses, whose dismal prognosis is further com-
pounded when early relapse (within 18 months from first-
line treatment) is observed.59,60
The negative impact of adverse cytogenetics on clinical
outcomes was not overcome by allogeneic HCT in our
series. More aggressive plasma cell clones may have
escaped graft-versus-myeloma effects after non-myeloab-
lative 2 Gy TBI. Instead, the impact of certain high-risk
cytogenetics was partly neutralized by graft-versus-myelo-
ma effects in a study by Kröger et al.61 on 73 patients treat-
ed with autologous HCT followed by reduced-intensity
melphalan 140 mg/m2 plus fludarabine, where no signifi-
cant differences in PFS between patients with del(17p13)
and/or t(4;14) and those without these abnormalities were
observed after a median follow up of six years. A French
trial also showed no differences in clinical outcomes
between t(4;14) and non-t(4;14) patients.62 Another study
by Rasche et al.63 showed no differences in survival out-
comes in patients carrying del(17p), t(4;14) or amp(1q21)
as compared to those with normal cytogenetics. We spec-
ulated that the incorporation of melphalan 140 mg/m2, as
employed in the studies by Kroger and Rasche, in the con-
ditioning regimen before allogeneic HCT added more
cytotoxicity and might have resulted in superior tumor
cell-kill and, therefore, better survival among those with
high-risk cytogenetics. Moreover, almost 50% of our
patients with adverse cytogenetics did not receive “new
agents” as part of induction treatment that, in part, are
able to overcome certain high-risk genetic features.64
In summary, our study showed that tandem autolo-
gous/minimal intensity allogeneic HCT for MM was safe
and characterized by low acute and long-term toxicities.
Patients among standard and high-risk categories were
able to achieve long-term sustained remissions, while
patients with ultra-high-risk disease did not benefit from
the tandem HCT. Similarly, patients with progressive dis-
ease after autologous HCT failed to respond to allogeneic
HCT and succumbed to the disease, suggesting that 
graft-versus-myeloma effects alone are inadequate to con-
trol refractory and high-tumor burden disease states.
Allogeneic HCT may be employed as a platform for post-
transplant immune-based strategies such as novel
immunomodulatory drugs or proteasome inhibitors, CAR
T- and N-cell infusions, and bispecific T-cell engagers in
selected high-risk populations where prognosis remains
poor even in the era of new drugs.65-67
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